Loading...

HURA TUHURA BIOSCIENCES INC Delisting Actions 8-K Filing

THR

HR

TUHURA BIOSCIENCES INC

(HURA)

2023 8-K

Financial Results Update

Nasdaq Compliance Notice

Stock Offering Announcement

Loan Agreement Amendment

Shelf Registration Update

Financial Update

Stock Offering Agreement

Business Updates

Bridge Loan Agreement

Funding Agreement Update

Financial Results Report

Merger of Equals

Merger of Equals

Compensatory Arrangements o...

Merger of Equals

Merger of Equals

Investor Presentation

Board Appointment

Warrant Exercise Notes

Merger Completion

Merger Agreement

Merger Announcement

Executive Compensation

Merger Completion

Merger Announcement

Merger Announcement

Financial Update

Merger Approval

Merger Agreement

Merger Announcement

Clinical Trial Update

Merger Announcement

Merger Vote Reminder

Proposed Merger

Clinical Trial Update

Termination of Preferred St...

Acquisition Agreement

Corporate and Clinical Adva...

Annual Meeting of Stockholders

Delisting Notice

Clinical Trial Results

Results of Operations and F...

Shareholder Director Nomina...

Clinical Trial Results Acce...

Merger Agreement

Nasdaq Compliance

Nasdaq Compliance

Earnings Release

Clinical Trial Initiation

Increase in Offering Price

Delisting Notice

Exploring Strategic Alterna...

Delisting Notice

Management Changes

Financial Results

Preliminary Study Results

Special Meeting of Stockhol...

Delisting Notice

Sales Agreement

Financial Disclosure

Amendment to Articles of In...

Adjournment of Annual Meeting

Appointment of Interim CFO

Adjournment of Annual Meeting

Financial Update

Adjournment of Annual Meeting

Regulation FD Disclosure

Financial Results

External Links:

Kintara Therapeutics received notice from Nasdaq that it is not in compliance with the minimum stockholders equity requirement, but has been granted an extension to regain compliance.

AI Assistant

TUHURA BIOSCIENCES INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.